• EUropean Scleroderma Tirals and Research group (EUSTAR) must be acknowledged on every presentation/publication that results from accepted proposals.

  • EUSTAR centers providing samples and clinical data should be co-authors on manuscripts and presentations derived from the study (at least one per center) whenever possible. In case of a too high number of authors for the target journal, an adequate acknowledgement must be provided in the paper. Conflicts of interests in this matter will be decided by the Executive Officers If submitting centers do not agree with this procedure, they must clearly state this in the proposal. There are no exceptions from this rule. The sequence of authors is decided by the submitting center, but should in general be based on the numbers of cases/samples contributed to the study.
  • The intellectual content of the proposal belongs to the submitting center. Misuse of the proposal for own studies is strictly forbidden.

The caretaker officers positions will be opened to candidature and there being no alternative nominations, election by closed written ballot will take place by one representative of every EUSTAR members eligible to vote.

The caretaker officers will be elected by an overwhelming majority (>50%), supervised by the appropriate World Scleroderma Foundation officer

According to the EUSTAR statute, election is for 3 years with an option to continue for another 3 years. Officers can be re-elected only in a different position.

The following positions are open to election:

  • President
  • Secretary
  • Treasurer
  • Councellors (4)

The past board will present the names for nomination. Any other colleague or group of colleagues can be nominated for election. This one must be EUSTAR member.

In April, before the elections taking place during the EULAR congress in June, an announcement will be made asking all EUSTAR members for nominations. Nominations must arrive at the EUSTAR secretariat before the end of April. Nominations will be collected and the names will be put forward for election.

Committee members will be chosen by the board (after the elections of officers) and proposed to the general assembly for ratification.

The next new board (chairman, treasurer, secretary) will be elected and will start to work with the help of previous board in order to shape up the EUSTAR programme of the next triennium.

  • Eustar will foster the application from Eustar members.
  • Eustar will allow also non members to apply. The work must be then published under Eustar committee overview and approval.
  • Eustar submission form must be used
  • Application must be forwarded directly to the chairman of the Committee.
  • If the project is not covered by the Ethical Committee approval for the database (MEDS-online), the applicant must obtain local approval and approval for each of the participants.
  • Review will be performed by the committee (at least 2 independent reviewers) within 4 weeks.
  • The result of the review will be forwarded to the chairman and the board. The board will send its final decision to the chairman of the committee and the applicant within 2 weeks after the receipt of the reviewers’ comment
  • Revisions can be suggested to applicants.
  • The advancement of the projects should be provided every 6 months to the chairman of Clinical or Research committees.
  • The chairman of the committee must inform the Eustar chairman of the advancement of the work.
  • The advancement of the project will be presented each year at the business meeting.
  • A project has to move forward and may be closed if nothing is moving including publication.
  • Submission of abstracts must be validated by the Board or by the chairman in case it is later.
  • Publications must fulfill the rules of authorship and must be sent to the board before submission.
  • EULAR meeting and Annals of the Rheumatic Diseases should be first targeted for presentation of the results

DNA is property of the patient and of the Eustar centre that has delivered it. If other experiments than that included in the Eustar project in its approved version are considered a simple but formal request should be mailed to the committee in charge of the project (basic or clinical) to obtain permission and thereafter to the co-investigators taking care in particular of ethical issues.

All EUSTAR manuscripts, approved by the EUSTAR Board and bearing the name of EUropean Scleroderma Trials and Research (EUSTAR) in the title, before being submitted to a journal, must follow a specific pathway:
According to EUSTAR rules all EUSTAR manuscripts must be submitted to committee chairman before sending to any journal for comment which takes two weeks.
The preferred journal is Ann Rheum Dis, but this is optional. If “recommendations”, “points to consider” or “criteria” are in the title, then Ann Rheum Dis must be the first choice.
Please, follow these rules in order to avoid any problem in the future. Informal projects arranged between various EUSTAR centres which have not been approved by the EUSTAR board are not allowed to use the words EUSTAR in the title.
For any information, contact always the chairman or the Secretariat.

  • It has been decided by all members that companies may have access to data presented on the database for special purposes. EUSTAR will be the interface between companies and centres that have filled the database. When a company wants data collected in EUSTAR centres, they have to ask EUSTAR and once approved, they will pay EUSTAR that will use the money to maintain the datased system and improve the quality and content of the database. After cross consultation the following fees were decided:
  • Regular updates on demographics from the MEDS for a fixed annual fee (€ 20,000)
  • NO details of centres
  • Ad hoc project based studies with fee according to amount of work required. All negotiations between EUSTAR board and Company only.

The Companies will have no access to raw data, no influence over statistical analysis and no veto rights on the final publications. Only centres in which patients have given permission for anonymous data use will participate (this is an intrinsic part of the MEDS on-line participation)